Freeze All on Oocyte Maturatin by Gonadotropin Agonist Versus Human Chorionic Gonadotroipin

What Was Tested

In this not phased trial, researchers set out to test Triptorelin.

It had two arms (groups): giving agonist ( eg. decapeptyl ) (active comparator) and Giving HCG (eg. choriomon ) (active comparator).

Giving women agonist.

Giving women HCG.

The registry classes the interventions as drug.

More on the Plan

U/S was done on day 9 or 10 of cycle to assess endometrial thickness, then every other day until endometrial thickness of 8 mm or more is reached and when endometrial thickness reaches 8 mm or more FET was planned.

Who Took Part

The registry lists 100 planned participants were the target.

It was open to women only aged from 18 years up to 42 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: PCOS patients according to Rotterdam criteria. Female age between 20 and 40 years. Primary or secondary infertility. Body mass index (BMI) between 18 and 40 kg/m2.

The full record lists 4 inclusion and 3 exclusion criteria; among the exclusions: ovarian endometriosis; ovarian cysts before induction; known uncontrolled endocrinal abnormalities (like hypo or hyperthyroidism).

How the Study Was Run

It was run as a randomized, parallel-group and double-blind study.

Random assignment meant chance, not the researchers, decided who got Triptorelin and who got the comparison, which limits bias.

The Triptorelin group and the comparison group ran side by side rather than switching.

Neither the participants nor the staff measuring them knew who was on Triptorelin, so expectations could not easily colour the readings.

Those kept unaware of assignments: investigator and outcomes assessor.

It started in 2021-02-05 with completion listed for 2021-06-25.

It ran at 1 site in Egypt.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: the number of good quality embryos (time frame: within 5 months).

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Triptorelin in 100 people.

Its status is unknown; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Triptorelin compound page, all human trials.